stief marco (54 resultados)

HRD. Condición: New. New Book. Shipped from UK. Established seller since 2000.

HRD. Condición: New. New Book. Shipped from UK. Established seller since 2000.

Buch. Condición: Neu. Neuware -A skinny label application permits a generics manufacturer to seek market approval solely for the unpatented uses of the drug by excluding or carving out the patented use from the Summary of Product Characteristics and the product leaflet (or from its label). As the practice becomes more widespread globally, questions arise about the different national approaches towards ?skinny labels? and conformity with patent law.With contributions from highly qualified and experienced patent litigators from across the globe, this book provides a comprehensive legal study on the current legal situation of skinny labelling in Europe, the United States, Australia, and Asia, giving key information in particular on interpretation of patent claims, direct and indirect infringement, an applicable domestic legislation.This book is ideal for in-house counsel in the pharmaceutical industry and legal practitioners. 406 pp. Englisch.

Buch. Condición: Neu. Neuware -A skinny label application permits a generics manufacturer to seek market approval solely for the unpatented uses of the drug by excluding or carving out the patented use from the Summary of Product Characteristics and the product leaflet (or from its label). As the practice becomes more widespread globally, questions arise about the different national approaches towards ?skinny labels? and conformity with patent law.With contributions from highly qualified and experienced patent litigators from across the globe, this book provides a comprehensive legal study on the current legal situation of skinny labelling in Europe, the United States, Australia, and Asia, giving key information in particular on interpretation of patent claims, direct and indirect infringement, an applicable domestic legislation.This book is ideal for in-house counsel in the pharmaceutical industry and legal practitioners. 406 pp. Englisch.

Buch. Condición: Neu. Neuware -A skinny label application permits a generics manufacturer to seek market approval solely for the unpatented uses of the drug by excluding or carving out the patented use from the Summary of Product Characteristics and the product leaflet (or from its label). As the practice becomes more widespread globally, questions arise about the different national approaches towards skinny labels and conformity with patent law.

Condición: New. Stief Supplementary Protection Certificates Supplementary protection certificates (SPC) extend the effects of patents for medicinal products by a maximum of five and a half years, i.e. the certificate becomes effective at a time wh.

Condición: New. A skinny label application permits a generics manufacturer to seek market approval solely for the unpatented uses of the drug by excluding or carving out the .

Condición: Brand New. 400 pages. 6.57x0.98x9.72 inches. In Stock.

Buch. Condición: Neu. Neuware -A skinny label application permits a generics manufacturer to seek market approval solely for the unpatented uses of the drug by excluding or carving out the patented use from the Summary of Product Characteristics and the product leaflet (or from its label). As the practice becomes more widespread globally, questions arise about the different national approaches towards skinny labels and conformity with patent law.C.H. Beck, Wilhelmstrasse 9, 80801 München 406 pp. Englisch.

Buch. Condición: Neu. Neuware - A skinny label application permits a generics manufacturer to seek market approval solely for the unpatented uses of the drug by excluding or carving out the patented use from the Summary of Product Characteristics and the product leaflet (or from its label). As the practice becomes more widespread globally, questions arise about the different national approaches towards ?skinny labels? and conformity with patent law.With contributions from highly qualified and experienced patent litigators from across the globe, this book provides a comprehensive legal study on the current legal situation of skinny labelling in Europe, the United States, Australia, and Asia, giving key information in particular on interpretation of patent claims, direct and indirect infringement, an applicable domestic legislation.This book is ideal for in-house counsel in the pharmaceutical industry and legal practitioners.

Buch. Condición: Neu. Infringement of Second Medical Use Claims | A global study focusing on skinny labels | Marco Stief (u. a.) | Buch | XXIV | Englisch | 2024 | C.H. Beck | EAN 9783406817533 | Verantwortliche Person für die EU: Verlag C.[.] GmbH & Co. KG, Wilhelmstr. 9, 80801 München, produktsicherheit[at]beck[dot]de | Anbieter: preigu.

Buch. Condición: Neu. Supplementary Protection Certificates (SPC) | A Handbook, Beck International | Marco Stief | Buch | XIV | Englisch | 2021 | C.H. BECK Verlag GmbH & [.] | EAN 9783406762406 | Verantwortliche Person für die EU: Verlag C.[.] GmbH & Co. KG, Wilhelmstr. 9, 80801 München, produktsicherheit[at]beck[dot]de | Anbieter: preigu.

Buch. Condición: Neu. Neuware - Stief Supplementary Protection Certificates Supplementary protection certificates (SPC) extend the effects of patents for medicinal products by a maximum of five and a half years, i.e. the certificate becomes effective at a time when the respective pharmaceutical is widely known on the market and thus generates the maximum revenue. This explains the enormous economic value of SPCs. They protect some of the most valuable products in the pharmaceutical industry. The legal basis for the SPC for medicinal products is a European Regulation. The obtaining provisions of that Regulation, the scope of protection etc. are highly disputed and have been the subject of numerous decisions of the CJEU. This handbook provides valuable insights into the world of SPCs and the most significant case law and legal sources at EU and national level of Germany, the UK, France, Italy, the Netherlands and Switzerland. The second completely revised edition specifically addresses recent developments of SPCs including manufacturing waivers and the implications of ?Brexit?.

HRD. Condición: New. New Book. Shipped from UK. Established seller since 2000.

Condición: New.

Condición: New.

HRD. Condición: New. New Book. Shipped from UK. Established seller since 2000.

Condición: As New. Unread book in perfect condition.

Gebunden. Condición: New. The topic of pharmaceutical, biological and chemical patents is a special matter within European and German patent law. There are several structural alterations, like polymorphism and enantiomerism, leading to a derivative of a substance that is compris.

Condición: As New. Unread book in perfect condition.

Buch. Condición: Neu. Neuware -Germany is a leading venue for patent litigation, with about 60% of European patent cases heard in its courts. Especially in pharmaceutical, biological, and chemical patents, German case law provides key interpretations and legal guidance, notably on issues like 'state of the art' and substance identification. This handbook highlights core principles and trends in German jurisprudence to support arguments across jurisdictions.Advantages at a glance:Structured overview of German patent lawEnglish translations of major rulingsFocus on pharma, bio, and chemical patent issues 1268 pp. Englisch.

Buch. Condición: Neu. Neuware -Germany is a leading venue for patent litigation, with about 60% of European patent cases heard in its courts. Especially in pharmaceutical, biological, and chemical patents, German case law provides key interpretations and legal guidance, notably on issues like 'state of the art' and substance identification. This handbook highlights core principles and trends in German jurisprudence to support arguments across jurisdictions.Advantages at a glance:Structured overview of German patent lawEnglish translations of major rulingsFocus on pharma, bio, and chemical patent issues 1268 pp. Englisch.

Buch. Condición: Neu. Neuware -The topic of pharmaceutical, biological and chemical patents is a special matter within European and German patent law. There are several structural alterations, like polymorphism and enantiomerism, leading to a derivative of a substance that is comprised in the prior art. This gives rise to the question under what circumstances such alterations can be novel and in which cases they are included in the state of the art. But even if a substance is prior art, a new medical use of it can be patented, as such medical use patents are politically intended to promote medical research.On the other hand, it is unclear how to deal with natural occurrences of a substance in terms of its accessibility and bioethics.It must also be understood how different identifications of a substance and the resulting patents interrelate with each other, i.e. how their scopes of protection are defined. This is problematic especially because of the absolute substance protection, which includes all conceivable uses and methods.The past decisions of the ECJ as regards broccoli- and to-mato-patents, as well as embryonic stem cells have highlighted the importance of this field of law.Most of the proceedings regarding pharmaceutical, biological and chemical patents are held in German courts. The German jurisprudence is also of importance to the subject matter, as it has often been the basis for decisions of the ECJ. Thus, German case law is used to illustrate the comments.Dr Maximilian Haedicke holds a chair in IP law at the University of Freiburg, Germany, and is judge at the Düsseldorf Regional Court of Appeal.Dr Marco Stief, LL.M. and Dr Dirk Bühler are patent attorneys and partners in Maiwald Patentanwälte in Munich, Germany.

Buch. Condición: Neu. Neuware -The topic of pharmaceutical, biological and chemical patents is a special matter within European and German patent law. There are several structural alterations, like polymorphism and enantiomerism, leading to a derivative of a substance that is comprised in the prior art. This gives rise to the question under what circumstances such alterations can be novel and in which cases they are included in the state of the art. But even if a substance is prior art, a new medical use of it can be patented, as such medical use patents are politically intended to promote medical research.On the other hand, it is unclear how to deal with natural occurrences of a substance in terms of its accessibility and bioethics.It must also be understood how different identifications of a substance and the resulting patents interrelate with each other, i.e. how their scopes of protection are defined. This is problematic especially because of the absolute substance protection, which includes all conceivable uses and methods.The past decisions of the ECJ as regards broccoli- and to-mato-patents, as well as embryonic stem cells have highlighted the importance of this field of law.Most of the proceedings regarding pharmaceutical, biological and chemical patents are held in German courts. The German jurisprudence is also of importance to the subject matter, as it has often been the basis for decisions of the ECJ. Thus, German case law is used to illustrate the comments.Dr Maximilian Haedicke holds a chair in IP law at the University of Freiburg, Germany, and is judge at the Düsseldorf Regional Court of Appeal.Dr Marco Stief, LL.M. and Dr Dirk Bühler are patent attorneys and partners in Maiwald Patentanwälte in Munich, Germany. 1288 pp. Englisch.

Buch. Condición: Neu. Neuware -The topic of pharmaceutical, biological and chemical patents is a special matter within European and German patent law. There are several structural alterations, like polymorphism and enantiomerism, leading to a derivative of a substance that is comprised in the prior art. This gives rise to the question under what circumstances such alterations can be novel and in which cases they are included in the state of the art. But even if a substance is prior art, a new medical use of it can be patented, as such medical use patents are politically intended to promote medical research.On the other hand, it is unclear how to deal with natural occurrences of a substance in terms of its accessibility and bioethics.It must also be understood how different identifications of a substance and the resulting patents interrelate with each other, i.e. how their scopes of protection are defined. This is problematic especially because of the absolute substance protection, which includes all conceivable uses and methods.The past decisions of the ECJ as regards broccoli- and to-mato-patents, as well as embryonic stem cells have highlighted the importance of this field of law.Most of the proceedings regarding pharmaceutical, biological and chemical patents are held in German courts. The German jurisprudence is also of importance to the subject matter, as it has often been the basis for decisions of the ECJ. Thus, German case law is used to illustrate the comments.Dr Maximilian Haedicke holds a chair in IP law at the University of Freiburg, Germany, and is judge at the Düsseldorf Regional Court of Appeal.Dr Marco Stief, LL.M. and Dr Dirk Bühler are patent attorneys and partners in Maiwald Patentanwälte in Munich, Germany. 1288 pp. Englisch.

Condición: New. The topic of pharmaceutical, biological and chemical patents is a special matter within European and German patent law. Structural alternations give rise to the question under what circumstances they can be novel and in which cases they are included under s.

Condición: New.

Buch. Condición: Neu. Neuware - Germany is a leading venue for patent litigation, with about 60% of European patent cases heard in its courts. Especially in pharmaceutical, biological, and chemical patents, German case law provides key interpretations and legal guidance, notably on issues like 'state of the art' and substance identification. This handbook highlights core principles and trends in German jurisprudence to support arguments across jurisdictions.Advantages at a glance:Structured overview of German patent lawEnglish translations of major rulingsFocus on pharma, bio, and chemical patent issues.

Buch. Condición: Neu. Neuware -The topic of pharmaceutical, biological and chemical patents is a special matter within European and German patent law. There are several structural alterations, like polymorphism and enantiomerism, leading to a derivative of a substance that is comprised in the prior art. This gives rise to the question under what circumstances such alterations can be novel and in which cases they are included in the state of the art. But even if a substance is prior art, a new medical use of it can be patented, as such medical use patents are politically intended to promote medical research.On the other hand, it is unclear how to deal with natural occurrences of a substance in terms of its accessibility and bioethics.It must also be understood how different identifications of a substance and the resulting patents interrelate with each other, i.e. how their scopes of protection are defined. This is problematic especially because of the absolute substance protection, which includes all conceivable uses and methods.The past decisions of the ECJ as regards broccoli- and to-mato-patents, as well as embryonic stem cells have highlighted the importance of this field of law.Most of the proceedings regarding pharmaceutical, biological and chemical patents are held in German courts. The German jurisprudence is also of importance to the subject matter, as it has often been the basis for decisions of the ECJ. Thus, German case law is used to illustrate the comments.Dr Maximilian Haedicke holds a chair in IP law at the University of Freiburg, Germany, and is judge at the Düsseldorf Regional Court of Appeal.Dr Marco Stief, LL.M. and Dr Dirk Bühler are patent attorneys and partners in Maiwald Patentanwälte in Munich, Germany.C.H. Beck, Wilhelmstrasse 9, 80801 München 1268 pp. Englisch.

Buch. Condición: Neu. Neuware - The topic of pharmaceutical, biological and chemical patents is a special matter within European and German patent law. There are several structural alterations, like polymorphism and enantiomerism, leading to a derivative of a substance that is comprised in the prior art. This gives rise to the question under what circumstances such alterations can be novel and in which cases they are included in the state of the art. But even if a substance is prior art, a new medical use of it can be patented, as such medical use patents are politically intended to promote medical research.On the other hand, it is unclear how to deal with natural occurrences of a substance in terms of its accessibility and bioethics.It must also be understood how different identifications of a substance and the resulting patents interrelate with each other, i.e. how their scopes of protection are defined. This is problematic especially because of the absolute substance protection, which includes all conceivable uses and methods.The past decisions of the ECJ as regards broccoli- and to-mato-patents, as well as embryonic stem cells have highlighted the importance of this field of law.Most of the proceedings regarding pharmaceutical, biological and chemical patents are held in German courts. The German jurisprudence is also of importance to the subject matter, as it has often been the basis for decisions of the ECJ. Thus, German case law is used to illustrate the comments.Dr Maximilian Haedickeholds a chair in IP law at the University of Freiburg, Germany, and is judge at the Düsseldorf Regional Court of Appeal.Dr Marco Stief, LL.M.andDr Dirk Bühler are patent attorneys and partners in Maiwald Patentanwälte in Munich, Germany.